Want to see JP:4893 full AI Analyst Report?

Noile-Immune Biotech Inc. (4893) Price & Analysis

0 Followers

4893 Stock Chart & Stats

¥134.00

¥9.00(4.81%)

At close: Jan 08 4:00 PM EST

¥134.00

¥9.00(4.81%)

Day’s Range― - ―

52-Week Range¥114.00 - ¥217.00

Previous CloseN/A

Volume1.93M

Average Volume (3M)106.42K

Market Cap

¥6.03B

Enterprise Value¥1.70K

Total Cash (Recent Filing)¥3.54B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-17.40

Shares Outstanding43,399,117

10 Day Avg. Volume76,140

30 Day Avg. Volume106,423

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.46

Price to Sales (P/S)1151.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-18.33

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetThe absence of debt reduces interest obligations and refinancing exposure, giving the company greater flexibility while it funds biotechnology development. Although equity has declined with losses, the conservative capital structure provides a meaningful buffer against leverage-driven financial stress.

Very High Gross MarginsConsistently near-100% gross margins indicate that reported revenue carries substantial value after direct costs. If revenue stabilizes and commercialization progresses, this cost structure could provide strong operating leverage, allowing future sales growth to contribute disproportionately to gross profit.

Recent Improvement In LossesThe narrower 2025 loss represents an initial improvement in financial trajectory after substantial prior deterioration. If maintained, better cost discipline could extend the company’s funding runway and reduce the pace at which ongoing development activities consume equity.

Bears Say

Sharp Revenue ContractionLarge and repeated revenue declines weaken evidence of commercial traction and make the business model difficult to scale predictably. Continued volatility can delay operating leverage, restrict internal funding capacity, and leave future results highly dependent on renewed revenue growth.

Persistent Operating Cash BurnNegative operating cash flow across every reported year shows that the business has not yet self-funded its operations. Even with no debt, sustained cash consumption may require further equity funding and can erode the resources available for development and commercialization.

Deep UnprofitabilityLarge recurring losses and a deeply negative net margin indicate that current revenue is insufficient to support the company’s cost base. This limits earnings visibility, weakens returns on shareholder capital, and increases dependence on successful future commercialization to achieve profitability.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥114.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥6.03B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 55 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Aug 13, 2026. The company reported -¥5.05 earnings per share for the quarter, beating the consensus estimate of -¥5.51 by ¥0.46.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,399,117 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥5.05 in its last earnings report, beating expectations of -¥5.51. Following the earnings report the stock price went up 0.714%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.